Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge

Journal of Controlled Release

Volumn 148, Issue 2, 2010, Pages 177-186

  Dadashzadeh, S ^a   Mirahmadi, N ^a   Babaei, M H ^b   Vali, A M ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ATOMIC ENERGY ORGANIZATION OF IRAN   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

99mTc HMPAO; Liposome charge; Liposome composition; PEG coating; Peritoneal retention; Tissue distribution

Indexed keywords

99MTC-HMPAO; LIPOSOME CHARGE; PEG COATING; PERITONEAL RETENTION; TISSUE DISTRIBUTION;

CHEMOTHERAPY; COATINGS; CONTROLLED DRUG DELIVERY; LIPOSOMES; PROPANE; TISSUE;

PHOSPHOLIPIDS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; DIMIRISTOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; LIPOSOME; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; HYDROPHILICITY; ISOTOPE LABELING; LIPID COMPOSITION; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEAL CAVITY; PRIORITY JOURNAL;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG COMPOUNDING; FATTY ACIDS, MONOUNSATURATED; FEMALE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INJECTIONS, INTRAPERITONEAL; LIPOSOMES; MICE; PARTICLE SIZE; PERITONEAL LAVAGE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; QUATERNARY AMMONIUM COMPOUNDS; RADIOPHARMACEUTICALS; SURFACE PROPERTIES; TECHNETIUM TC 99M EXAMETAZIME; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION;

EID: 78649318605     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.08.026     Document Type: Article

References (45)

1. de Bree E., Witkamp A.J., Zoetmulder F.A. Intraperitoneal chemotherapy for colorectal cancer. J. Surg. Oncol. 2002, 79:46-61.
2. Van der Speeten K., Stuart O.A., Sugarbaker P.H. Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr. Drug Discov. Technol. 2009, 6:72-81.
3. Pourgholami M.H., Akhter J., Wang L., Lu Y., Morris D.L. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother. Pharmacol. 2005, 55:425-432.
4. Hirano K., Anthony Hunt C., Strubbe A., MacGregor R.D. Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration - effect of lipid composition. Pharm. Res. 1985, 74:271-278.
5. Daoud S.S. Combination chemotherapy of human ovarian xenografts with intraperitoneal liposome-incorporated valinomycin and cis-diaminedichloroplatinum (II). Cancer Chemother. Pharmacol. 1994, 33:307-312.
6. 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model. Cancer Biother. Radiopharm. 2009, 24:453-460.
7. Sadzuka Y., Nakai S.-i., Miyagishima A., Nozawa Y., Hirota S. Effects of administered route on tissue distribution and antitumor activity of polyethyleneglycol-coated liposomes containing adriamycin. Cancer Lett. 1997, 111:77-86.
8. 111In-DTPA-labelled pegylated liposomes after intraperitoneal injection. Acta Oncol. 2003, 42:147-153.
9. 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl. Med. Biol. 2007, 34:415-423.
10. Verschraegen C.F., Kumagai S., Davidson R., Feig B., Mansfield P., Lee S.J., Maclean D.S., Hu W., Khokhar A.R., Siddik Z.H. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1, 2-diaminocyclohexane)platinum II entrapped in multilamellar liposome vesicles. J. Cancer Res. Clin. Oncol. 2003, 129:549-555.
11. Zavaleta C.L., Phillips W.T., Soundararajan A., Goins B.A. Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model. Int. J. Pharm. 2007, 337:316-328.
12. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51(4):691-743.
13. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.-D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl Acad. Sci. USA 1991, 88:11460-11464.
14. Allen T.M., Hansen C.B., Lopes de Menezes D.E. Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev. 1995, 16:267-284.
15. Khan D.R., Rezler E.M., Lauer-Fields J., Fields G.B. Effects of drug hydrophobicity on liposomal stability. Chem. Biol. Drug Des. 2008, 71:3-7.
16. Oussoren C., Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. 2001, 50:143-156.
17. Oussoren C., Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). Pharm. Res. 1997, 14(10):1479-1484.
18. Aramaki Y., Akiyama K., Hara T., Tsuchiya S. Recognition of charged liposomes by rat peritoneal and splenic macrophages: effects of fibronectin on the uptake of charged liposomes. Eur. J. Pharm. Sci. 1995, 3:63-70.
19. Sadzuka Y., Hirota S., Sonobe T. Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. Toxicol. Lett. 2000, 116:51-59.
20. Li L.C., Tian Y. Zeta potential. Encyclopedia of pharmaceutical technology 2007, 4117-4128. Informa Healthcare, New York. third edition. J. Swarbrick (Ed.).
21. Mirahmadi N., Babaei M.H., Vali A.M., Dadashzadeh S. Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice. Int. J. Pharm. 2010, 383(1-2):7-13.
22. 99mTc-HMPAO labeled liposomes: an investigation into the effects of some formulation factors on labeling efficiency and in-vitro stability. Nucl. Med. Biol. 2008, 35:387-392.
23. Stewart J.C.M. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 1980, 104:10-14.
24. Phillips W.T., Rudolph A.S., Goins B., Timmons J.H., Klipper R., Blumhardt R. A simple method for producing a Technetium-99m-labeled liposome which is stable in vivo. Nucl. Med. Biol. Int. j. Radiat. Appl. Instrum. Part B 1992, 19(5):539-547.
25. Maincent P., Thouvenot P., Amicabile C., Hoffman M., Kreuter J., Couvreur P., Devissaguet J.P. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration inrats. Pharm. Res. 1992, 9(12):1534-1539.
26. Shargel L., Wu-Pong S., Yu A.B.C. Applied biopharmaceutics & pharmacokinetics 2004, Mc Graw Hill.
27. Bailer A.J. Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacokin. Biopharm. 1988, 16(3):303-309.
28. Neirinckx R.D., Canning L.R., Piper I.M., Nowotnik D.P., Pickett R.D., Holmes R.A., Volkert W.A., Forster A.M., Weisner P.S., Marriott J.A., Chaplin S.B. Technetium-99m d, l-HMPAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J. Nucl. Med. 1987, 28(2):191-202.
29. Nagayasu A., Uchiyama K., Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev. 1999, 40:75-87.
30. Levchenko T.S., Rammohan R., Lukyanov A.N., Whiteman K.R., Torchilin V.P. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int. J. Pharm. 2002, 240(1-2):95-102.
31. Flessner M.F., Dedrick R.L., Schultz J.S. A distributed model of peritoneal-plasma transport: theoretical considerations. Am. J. Physiol. 1984, 246:R597-R607.
32. Howell S.B. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int. J. Gynecol. Cancer 2008, 18(Suppl. 1):20-25.
33. Hawley A.E., Davis S.S., Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv. Drug Deliv. Rev. 1995, 17:129-148.
34. Moghimi S.M. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials 2006, 27:136-144.
35. 2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation. Biochim. Biophys. Acta 2008, 1778:51-55.
36. Michailova K., Wassilev W., Wedel T. Scanning and transmission electron microscopic study of visceral and parietal peritoneal regions in the rat. Ann. Anat. 1999, 181:253-260.
37. Carr I. The Macrophage: a Review of Ultrastructure and Function 1973, Academic Press.
38. Rovira-Bru M., Thompson D.H., Szleifer I. Size and structure of spontaneously forming liposomes in lipid/PEG-lipid mixtures. Biophys. J. 2002, 83:2419-2439.
39. Vermehren C., Jorgensen K., Frokjaer S. Influence of lipopolymer concentration on liposome degradation and blood clearance. Int. J. Pharm. 1999, 183:13-16.
40. Jorgensen K., Kiebler T., Hylander I., Vermehren C. Interaction of a lipid-membrane destabilizing enzyme with PEG-liposomes. Int. J. Pharm. 1999, 183:21-24.
41. Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1991, 1062:142-148.
42. Litzinger D.C., Buiting A.M.J., van Rooijen N., Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta 1994, 1190:99-107.
43. Baradi A.F., Rao S.N. A scanning electron microscope study of mouse peritoneal mesothelium. Tissue Cell 1976, 8(1):159-162.
44. Phillips W.T. Delivery of gamma-imaging agents by liposomes. Adv. Drug Deliv. Rev. 1999, 37:13-32.
45. Marchettini P., Stuart O.A., Mohamed F., Yoo D., Sugarbaker P.H. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother. Pharmacol. 2002, 49(6):499-503.